Home / Stocks / Medicamen Biotech Limited
MEDICAMEQ

Medicamen Biotech Limited Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹287.4

Change

-2.35 (-0.81%)

Open

₹292.35

Prev. Close

₹289.75

Day High

₹295.0

Day Low

₹285.0

Volume Analysis

Traded

2,608

Delivered

61,303

Delivery %

47.66%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (3)

  • •Low return on equity (3.95%)
  • •Promoter holding is falling
  • •Below-average fundamentals quality score (43/100)

Opportunities (1)

  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹303.26 ₹299.13 ₹293.26 ₹289.13 ₹283.26 ₹279.13 ₹273.26
Fibonacci ₹299.13 ₹295.31 ₹292.95 ₹289.13 ₹285.31 ₹282.95 ₹279.13
Camarilla ₹290.15 ₹289.23 ₹288.32 ₹289.13 ₹286.48 ₹285.57 ₹284.65

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

-24.68%

1 Week

+5.74%

1 Month

+8.64%

3 Months

+17.52%

6 Months

+6.62%

1 Year

-28.92%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹203.97

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

8.52%

Net margin 5.71% × asset turnover 0.95x × equity multiplier 1.57x

Company Overview

Sector

Healthcare

Market Cap

₹407 Cr

P/E (TTM)

35.2

ROE

3.95%

Book Value

₹208.0

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 19 Nov 2026. Not investment advice.

TopFund Analysis

Medicamen Biotech Limited scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 43/100. The strongest factor is Financial Strength (100/100), while Cash Flow (0/100) is the weakest area to weigh before deciding. Notably: Low return on equity (3.95%); promoter holding is falling. FII holding has been rising.

TopFund Score — Fundamentals Quality

43/100 — Weak

Data confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

29

Valuation

38

Cash Flow

0

Corporate Governance

66

Momentum

33

Institutional Ownership

33

Business Quality

42

Risk & Volatility

37

Liquidity

27

From Screener.in

  • +Company is expected to give good quarter
  • +Promoter holding has increased by 2.11% over last quarter.
  • −The company has delivered a poor sales growth of 11.9% over past five years.
  • −Company has a low return on equity of 4.23% over last 3 years.
  • −Dividend payout has been low at 14.5% of profits over last 3 years
  • −Company has high debtors of 151 days.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 44 47 47 43 45 45 30 43 47 47 61 48 55
Expenses + 39 42 42 40 39 38 31 38 42 43 55 44 46
Operating Profit 5 5 6 3 5 7 -2 5 5 4 5 4 9
OPM % 10.68% 10.54% 12.15% 8.01% 11.87% 14.86% -5.44% 10.71% 10.94% 9.34% 8.95% 9.04% 15.83%
Other Income + 1 1 1 1 0 0 5 0 0 1 2 1 0
Interest 1 1 2 1 1 1 1 1 1 1 0 1 2
Depreciation 2 2 2 2 3 2 0 2 2 2 2 2 2
Profit before tax 2 3 3 2 2 4 2 2 3 2 5 3 5
Tax % 39.68% 38.11% 22.93% 48.72% 53.85% 24.74% 25.3% 24.88% 21.27% 22.27% 12.06% 28.4% 19.53%
Net Profit + 1 2 2 1 1 3 2 2 2 2 4 2 4
EPS in Rs 1 2 2 1 1 3 2 2 2 2 3 2 3
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 30 31 22 3 3 -3 -37 0 5 4 105 11 16

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 78 67 82 112 123 125 113 115 141 179 163 198 210
Expenses + 73 62 71 95 105 106 93 91 117 156 148 177 187
Operating Profit 5 6 12 17 17 20 20 24 24 24 14 21 23
OPM % 6.0% 8.0% 14.0% 15.0% 14.0% 16.0% 17.0% 21.0% 17.0% 13.0% 9.0% 10.0% 11.0%
Other Income + 1 1 0 2 4 2 1 2 2 2 6 3 3
Interest 4 4 4 3 1 1 2 2 3 6 4 5 4
Depreciation 2 2 2 2 2 2 3 6 6 7 7 7 7
Profit before tax 0 1 6 14 18 18 16 18 17 13 10 12 15
Tax % -267.0% 32.0% 19.0% 27.0% 31.0% 26.0% 26.0% 18.0% 14.0% 27.0% 34.0% 18.0% —
Net Profit + 0 0 5 10 12 13 12 15 15 9 7 10 12
EPS in Rs 0 0 5 9 10 11 10 12 12 9 6 7 9
Dividend Payout % 0.0% 0.0% 0.0% 12.0% 10.0% 5.0% 10.0% 8.0% 9.0% 12.0% 18.0% 14.0% —
Sales growth 6 -14 23 35 — 2 -10 2 22 27 -9 22 27

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 8 8 16 63 75 109 121 134 181 194 200 262 268
Borrowings + 21 19 18 14 12 11 19 26 26 31 34 49 41
Other Liabilities + 31 23 29 28 38 49 42 53 59 56 50 47 37
Total Liabilities 69 60 73 118 137 181 194 226 279 295 297 372 360
Fixed Assets + 20 19 19 25 24 34 90 92 93 92 87 85 82
CWIP 0 0 0 0 15 40 0 0 0 0 0 0 0
Investments 0 0 0 0 0 0 0 0 0 0 0 0 0
Other Assets + 49 41 54 92 97 107 104 133 186 203 210 287 278
Total Assets 69 60 73 118 137 181 194 226 279 295 297 372 360
Equity Capital 10 10 11 12 12 12 12 12 13 13 13 14 14

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + -3 6 4 -5 4 13 13 4 -6 -7 -8 -33
Cash from Investing Activity + 0 -1 -2 -8 -15 -37 -18 -8 -6 -6 -1 -3
Cash from Financing Activity + 3 -5 -1 33 -4 19 6 4 29 6 -1 64
Net Cash Flow 0 0 0 20 -14 -5 1 0 17 -6 -11 28
Free Cash Flow -3 5 1 -14 -11 -25 -5 -4 -13 -13 -10 -38
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit -65 112 31 -29 48 88 88 30 -13 -16 -47 -150

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 43.21% → 42.57%
  Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026 Oct 2026
Public 55.69% 55.78% 55.79% 56.04% 55.99% 58.83% 58.84% 59.02% 59.39% 59.01% 55.0% 53.01%
Promoters 43.21% 42.99% 42.99% 42.99% 43.16% 40.46% 40.46% 40.46% 40.46% 40.46% 40.46% 42.57%
Government 0.0% 0.0% 0.0% 0.06% 0.06% 0.05% 0.05% 0.05% 0.05% 0.05% 0.05% 0.05%
FII 0.12% 0.06% 0.06% 0.06% 0.12% 0.0% 0.05% 0.02% 0.1% 0.07% 4.49% 4.35%
DII 0.99% 1.17% 1.17% 0.87% 0.69% 0.64% 0.59% 0.44% 0.0% 0.4% 0.0% 0.0%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Medicamen Biotech Limited (this stock) 407 35.2 1.39 3.95%
Qms Medical Allied S Ltd 336 31.3 3.23 10.4%
Lyka Labs Ltd. 328 — 3.39 -10.2%
Haleos Labs Limited 494 38.1 2.25 8.44%
Ambalal Sarabhai Ent L 304 19.6 1.86 12.4%
Nureca Limited 293 61.4 1.56 1.12%
Valiant Laboratories Ltd 570 35.2 1.72 -2.55%

Which Mutual Funds Hold Medicamen Biotech Limited?

Frequently Asked Questions about Medicamen Biotech Limited

Community Sentiment

What are other investors saying about Medicamen Biotech Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.